We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Appealing Decision That Paved Way for First U.S. Biosimilar Entry
Amgen Appealing Decision That Paved Way for First U.S. Biosimilar Entry
Amgen, in an expected move, is appealing a federal judge’s decision that cleared the way for Sandoz to launch Zarxio, its biosimilar of Amgen’s chemotherapy product Neupogen.